Monday, November 06, 2023
Today, XtalPi, a globally renowned technology company that specializes in fusing artificial intelligence (AI) and robotics for pioneering advancements in medicine and innovative materials, has announced a new collaboration with CK Life Sciences, a member of the CK Hutchison Group. This partnership builds upon their existing relationship, wherein the two companies will merge AI algorithms with anonymized clinical and biomarker data from CK Life Sciences' data repository, encompassing cancer patients and healthy individuals. The objective of this collaboration is to jointly explore and develop molecular diagnostic models based on miRNA for predicting postoperative prognostic risks. By employing AI and machine learning models, this collaborative effort aims to create more sophisticated solutions for processing and modeling comprehensive multidimensional biomedical data, biomarker discovery, and forecasting postoperative recurrence risks.
Recent advances in experimental techniques within clinical research have generated a wealth of data from various dimensions, including genomics, cell biology, and tissue analysis. This, in conjunction with the rapid evolution of AI technologies, opens up unprecedented opportunities for clinical research and drug discovery. Early diagnosis, for instance, stands as a prime example, as improved AI prediction methods have the potential to preserve significant medical resources. In recent years, the decreasing cost of high-throughput sequencing has led to the accumulation of real-world mRNA and miRNA data in clinical treatment. AI algorithms offer exciting possibilities for extracting valuable insights from such large and complex datasets that surpass human capabilities. This innovative approach can identify new disease biomarkers and facilitate the development of efficient models for molecular diagnosis. The application of AI in this context holds great promise for accurately predicting postoperative prognosis and recurrence risk among cancer patients while reducing the wastage of valuable medical resources, making it a topic of significant interest among healthcare professionals and industry experts.
XtalPi, a leading AI and robotics technology company with a strong track record in applying cutting-edge algorithms to life science research, brings unique advantages and extensive experience in modeling biological sequence data, particularly in proteins and genes. CK Life Sciences is actively involved in the research and development of therapeutic cancer vaccines and cancer diagnostics, with a repository of cancer biomarker and clinical data amassed through years of clinical research. CK Life Sciences aims to leverage its expertise and strategic relationships to revolutionize cancer care and enhance patient outcomes through pioneering research in cancer diagnostics.
In 2022, the two companies initiated a collaboration to jointly develop an AI tumor vaccine R&D platform, aiming to improve the discovery and design of tumor vaccines and accelerate the development of a broader range of vaccine types. This new agreement will focus on a specific type of cancer, with XtalPi constructing AI models based on extensive multidimensional molecular diagnostic data in CK Life Sciences' repository.
The primary goal of this project is to develop cutting-edge modeling capabilities for miRNA data. XtalPi and CK Life Sciences aspire to create clinically applicable, high-precision tumor diagnostic tools that can empower physicians to assess postoperative cancer recurrence risks more reliably and implement better-tailored treatment plans, ultimately improving patient survival rates and quality of life. Simultaneously, they will strive to identify critical biomarkers and develop robust computational models for clinical diagnosis, disease management, and the discovery of novel therapeutics. The models and methods resulting from this project will lay the foundation for future collaborations involving larger and more complex datasets.
In the future, these models and tools have the potential to be applied across a wide range of disease areas, extending their use to the analysis of diverse omics data, including genomics, proteomics, and metabolomics. This will enable the integration of multi-modal data, such as genomics and imaging data, to bolster crucial applications such as biomarker identification, clinical diagnosis, novel drug discovery, and drug repositioning.
XtalPi, expressed, "CK Life Sciences has an exceptional scientific team and a significant repository of high-quality clinical molecular diagnostic data, which is essential for this collaboration. When combined with XtalPi's expertise in AI model construction and experience in applying cutting-edge technologies like large language models, we anticipate groundbreaking breakthroughs in this collaboration and an accelerated development of superior molecular diagnostic solutions. We are excited to explore a set of AI solutions with CK Life Sciences that can be applied to various data types, enhancing biomarker discovery and clinical diagnosis for the benefit of patients worldwide."
CK Life Science, noted, "Diagnostic and prognostic tests play a crucial role in cancer management, representing a significant aspect of comprehensive cancer care. The timely detection of cancer enables early intervention, facilitating prompt treatment initiation. Concurrently, the identification of patients at higher risk of recurrence or disease progression aids in tailoring treatment strategies based on risk. Working with XtalPi's exceptional team of data scientists, we hope to leverage our collective strengths to develop innovative cancer molecular diagnostics that will lead to improved patient outcomes."
Source: prnewswire.com
